AKBA — Akebia Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $594.64m
- $581.46m
- $160.18m
- 30
- 30
- 84
- 46
Annual cashflow statement for Akebia Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -383 | -283 | -92.6 | -51.9 | -69.4 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 253 | 100 | -7.3 | 11.6 | 30.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -13.7 | -108 | -11 | -20.7 | -39.7 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -110 | -253 | -73.2 | -23.4 | -40.7 |
| Capital Expenditures | -0.317 | -0.059 | -0.114 | 0 | -0.033 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -39.7 | 40 | 0 | — | — |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -40 | 39.9 | -0.114 | 0 | -0.033 |
| Financing Cash Flow Items | — | 44.8 | 40 | 0 | -1.27 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 232 | 134 | 14.6 | -25.2 | 49.7 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 81.3 | -79.3 | -58.7 | -48.6 | 8.97 |